A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.

被引：29
|
作者：
Papadopoulos, Kyriakos P.
Ou, Sai-Hong Ignatius
Johnson, Melissa Lynne
Christensen, James
Velastegui, Karen
Potvin, Diane
Faltaos, Demiana
Chao, Richard C.
机构：
[1] South Texas Accelerated Res Therapeut, San Antonio, TX USA
[2] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Orange, CA 92668 USA
[3] Sarah Cannon Res Inst, Nashville, TN USA
[4] Mirati Therapeut Inc, San Diego, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.TPS3161
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3161
引用
收藏
页数：1
相关论文
共 50 条
  • [1] KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.
    Sabari, Joshua K.
    Park, Haeseong
    Tolcher, Anthony W.
    Ou, Sai-Hong Ignatius
    Garon, Edward B.
    George, Ben
    Janne, Pasi A.
    Moody, Susan Elizabeth
    Tan, Eugene Y.
    Sen, Suman Kumar
    Peters, Dana
    Yan, Xiaohong
    Christensen, James G.
    Chi, Andrew S.
    Heist, Rebecca Suk
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [2] A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
    Spira, A.
    Riely, G.
    Lawler, W.
    Shum, M.
    Socinski, M.
    Yanagihara, R.
    Roshan, S.
    Kheoh, T.
    Christensen, J.
    Chao, R.
    Janne, P.
    Garassino, M.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S695 - S696
  • [3] KRYSTAL-16: A phase I/Ib trial of adagrasib (MRTX849) in combination with palbociclib in patients with advanced solid tumors with KRASG12C mutation.
    Sommerhalder, David
    Thevathasan, Jeena
    Ianopulos, Xenophon
    Volinn, Weining
    Hong, David
    CANCER RESEARCH, 2022, 82 (12)
  • [4] KRAS G12C inhibition using MRTX849: A novel radiosensitizing partner
    Milic, M.
    Laurent, P-A.
    Quevrin, C.
    Meziani, L.
    Morel, D.
    Signolle, N.
    Clemenson, C.
    Levy, A.
    Mondini, M.
    Deutsch, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S1159 - S1159
  • [5] KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation
    Johnson, M. L.
    Ou, S. H. I.
    Barve, M.
    Rybkin, I. I.
    Papadopoulos, K. P.
    Leal, T. A.
    Velastegui, K.
    Christensen, J. G.
    Kheoh, T.
    Chao, R. C.
    Weiss, J.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S2 - S2
  • [6] KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRASG12C mutation.
    Pant, Shubham
    Yaeger, Rona
    Spira, Alexander I.
    Pelster, Meredith
    Sabari, Joshua K.
    Hafez, Navid
    Barve, Minal A.
    Velastegui, Karen
    Yan, Xiaohong
    Der-Torossian, Hirak
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [7] Targeting the KRAS G12C Mutation in Patients With Advanced Solid Tumors
    Hong, David S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 612 - 614
  • [8] Phase I Study of JNJ-74699157 in Patients with Advanced Solid Tumors Harboring the KRAS G12C Mutation
    Wang, Judy
    Martin-Romano, Patricia
    Cassier, Philippe
    Johnson, Melissa
    Haura, Eric
    Lenox, Laurie
    Guo, Yue
    Bandyopadhyay, Nibedita
    Russell, Michael
    Shearin, Elizabeth
    Lauring, Josh
    Dahan, Laetitia
    ONCOLOGIST, 2022, 27 (07): : 536 - +
  • [9] KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced solid tumors harboring a KRASG12C mutation
    Pant, Shubham
    Yaeger, Rona
    Spira, Alexander I.
    Pelster, Meredith
    Sabari, Joshua K.
    Hafez, Navid
    Barve, Minal A.
    Velastegui, Karen
    Yan, Xiaohong
    Der-Torossian, Hirak
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36_SUPPL) : 425082 - 425082
  • [10] The anti-tumor activity of the KRAS G12C inhibitor MRTX849 is augmented by cetuximab in CRC tumor models
    Hallin, Jill
    Calinisan, Andrew
    Hargis, Lauren
    Aranda, Ruth
    Engstrom, Lars D.
    Briere, David M.
    Marx, Matthew A.
    Olson, Peter
    Christensen, James G.
    CANCER RESEARCH, 2020, 80 (16)
12345